Transcept Sees Road To Intermezzo Approval Without More Driving Studies
This article was originally published in The Pink Sheet Daily
Executive Summary
The company says FDA "generally agreed" with a proposal for dosing reductions and labeling changes for the middle-of-the-night insomnia drug, which has received two "complete response" letters.